Immunopathogenesis of recurrent vulvovaginal candidiasis.

Pl, Fidel; Jd, Sobel

doi:10.1128/cmr.9.3.335-348.1996

Cited by 62 publications

(93 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the potential use of antihistamine therapy was suggested. 24,25 Others have tried to stimulate humoral immune responses with vaccines based on Candida antigens, all with varying successes Values are given as means AE standard deviation or n (%). *Student's t test: normal women versus study subjects, P , 0.001. and none of which leading to clinical applications at this time.…”

Section: Discussionmentioning

confidence: 99%

Mannose‐binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis

Donders

Babula

Bellen³

et al. 2008

BJOG

View full text Add to dashboard Cite

Precis Women with recurrent vulvovaginal candidiasis (RVC) due to a polymorphism in codon 54 of the MBL2 gene respond better to fluconazole maintenance therapy than do women with other underlying causes.Objective To explain differences in response rates to maintenance therapy with fluconazole in women suffering from RVC by evaluating associations with a polymorphism in the gene coding for mannose-binding lectin (MBL).Design Follow-up study, neted case-control group.Setting Women attending vulvoginitis clinic for RVC.Population Women participating in a multicentric study in Belgium with a degressive dose of fluconazole for RVC (the ReCiDiF trial) were divided into good responders, intermediate responders and nonresponders according to the number of relapses they experienced during therapy. From 109 of these women with adequate follow-up data, vaginal lavage with 2 ml of saline were performed at the moment of a proven acute attack at inclusion in the study, before maintenance treatment was started. A buccal swab was obtained from 55 age-matched women without a history of Candida infections, serving as a control group.Methods Extracted DNA from buccal or vaginal cells was tested for codon 54 MBL2 gene polymorphism by polymerase chain reaction and endonuclease digestion.Main outcome measures Frequency of MBL2 condon 54 allele B in women with optimal or poor response to maintenance therapy in composition with controls.Results Women (n = 109) suffering from RVC were more likely to carry the variant MBL2 codon 54 allele B than control women (20 versus 6.6%, OR 3.4 [95% CI 1.3-8.2], P = 0.01). B alleles were present in 25% of the 36 women not suffering from any recurrence during the maintenance therapy with decreasing doses of fluconazole (OR 4.9 [95% CI 1.9-12.5], P = 0.0007 versus controls), in 20% of the 43 women with sporadic recurrences (OR 3.6 [95% CI 1.4-9.2], P = 0.007 versus controls) and in 15% of the 30 women who had to interrupt the treatment regimen due to frequent relapses (P = 0.097 versus controls).Conclusions The MBL2 codon 54 gene polymorphism is more frequent in Belgian women suffering from RVC than in controls. The presence of the B allele is associated with a superior response to fluconazole maintenance therapy as compared with RVC patients without this polymorphism. We conclude that RVC due to deficient MBL production is more easily helped with antifungal medication than is RVC due to some other mechanism.

show abstract

Section: Discussionmentioning

confidence: 99%

Mannose‐binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis

Donders

Babula

Bellen³

et al. 2008

BJOG

View full text Add to dashboard Cite

show abstract

“…So far, innate and humoral immunity and cell-mediated immunity are all involved in host defense against C. albicans infection [17]. Although the contribution of each appears to be site-speci¢c, innate immunity by polymorphonuclear neutrophils and macrophages dominates protection against systemic candidiasis.…”

Section: Discussionmentioning

confidence: 99%

Interaction of sertraline with Candida species selectively attenuates fungal virulence in vitro

LASSFLORL¹

2003

FEMS Immunology and Medical Microbiology

View full text Add to dashboard Cite

This study investigated whether the interaction between isolates of Candida albicans (n=7), Candida parapsilosis (n=3), Candida krusei (n=2), Candida dubliniensis (n=1) and sertraline, a typical selective serotonin reuptake inhibitor, alters candidal virulence. Sertraline treatment of Candida spp. significantly (P<0.05) affected hyphal elongation, phospholipase activity, production of secreted aspartyl proteinases and fungal viability. In addition, monocyte-derived macrophages (MDMs) treated with sertraline reduced inhibition of blastoconidia germination in comparison to MDMs alone. In conclusion, our findings suggest that the interaction between sertraline and Candida spp. may also diminish the virulence properties of this fungal pathogen in vivo.

show abstract

“…Vulvovaginal Candidiasis (VVC) is the second most common vaginal infection that associated with genital pruritus, white cheesy discharge, vaginal and urine irritation and dyspareunia. 1,2 It is estimated that about 70-75% of women suffer from Candidal vaginitis at least one occasion in their lifetime 1,3 and about 40-45% twice or more. Candida albicans accounts for 85-90% of fungal infections.…”

Section: Introductionmentioning

confidence: 99%

Comparing the effectiveness of Salvia officinalis, clotrimazole and their combination on vulvovaginal candidiasis: A randomized, controlled clinical trial

Ahangari

Farshbaf‐Khalili

Javadzadeh

et al. 2019

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim To determine the effect of vaginal tablet of Salvia officinalis, alone and in combination with Clotrimazole, on the recovery of Vulvovaginal candidiasis. Methods In this triple‐blind randomized controlled trial, 111 participants were randomly assigned into three groups of 37 patients using block randomization with block sizes of 6 and 9, and allocation ratio of 1:1:1: 100 mg vaginal tablet of Clotrimazole and Placebo (CP), 400 mg vaginal tablet of S. officinalis and Placebo (SP), and vaginal tablet of S. officinalis and Clotrimazole (SC), once daily for 7 days. On the seventh day after the treatment was ended up, Vulvovaginal candidiasis were examined by vaginal symptoms and wet test, and if positive, they were examined by culture in chrome agar Candida medium. Results Socio‐demographic characteristics was similar (P > 0.05). Thirty‐six, 36 and 35 patients, respectively in CP, SC and SP groups recruited in the study. The frequency of a positive wet test confirmed by Sabrodextrose agar medium 7 days after treatment was significantly lower in SC group than the reference group of CP (adjusted odds ratio = 0.09, 95% confidence interval: 0.93–0.932, P = 0.043). There was no significant difference between SP and CP group (P = 0.071, 95% confidence interval: 0.032–1.151, adjusted odds ratio = 0.192). Also, there was no significant difference between the three groups in terms of vaginal symptoms at the baseline (P > 0.05), however the statistical differences were indicated after the intervention in cheesy discharge, pruritus and Vulvovaginal edema (P < 0.05.(. Conclusion S. officinalis in the form of vaginal tablet, alone and when combined with Clotrimazole, can treat the Vulvovaginal Candidiasis.

show abstract

Immunopathogenesis of recurrent vulvovaginal candidiasis.

Abstract: BACKGROUND EPIDEMIOLOGY AND RATIONALE .

Cited by 62 publications

References 82 publications

Mannose‐binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis

Mannose‐binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis

Interaction of sertraline with Candida species selectively attenuates fungal virulence in vitro

Comparing the effectiveness of Salvia officinalis, clotrimazole and their combination on vulvovaginal candidiasis: A randomized, controlled clinical trial

Contact Info

Product

Resources

About